Condition: Low-grade Upper Tract Urothelial Carcinoma · Sponsor: Ferring Pharmaceuticals
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
This description comes directly from the study's public registry record.
Ferring Pharmaceuticals · 1-888-337-7464 · Disclosure@ferring.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Scottsdale Arizona | Scottsdale, Arizona, United States | Recruiting |
| Providence Saint John's Cancer Institute | Santa Monica, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Mayo Clinic - Rochester Minnesota | Rochester, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology | Philadelphia, Pennsylvania, United States | Recruiting |
| Baylor College of Medicine (Houston) | Houston, Texas, United States | Recruiting |
| MD Anderson Cancer Center - Genitourinary (GU) Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06668493